Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2021-08-24 Director's Dealing
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used by executives and major shareholders to report changes in their shareholdings in a listed company (Pharmabcine). This type of filing is classified as 'Director's Dealing' (DIRS) as it documents personal share transactions and ownership changes by company insiders.
2021-08-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (DART). This document details the shareholding changes of a company executive (Park Hyunsun of PharmAbcine). In the provided classification schema, reports of personal share transactions by company directors and executives are categorized as 'Director's Dealing'.
2021-08-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal shareholdings and changes therein. In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2021-08-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a mandatory disclosure by company insiders (directors/major shareholders) regarding their shareholdings and changes therein. In the provided taxonomy, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2021-08-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (insiders) of PharmAbcine. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership changes and thresholds.
2021-08-24 Korean
전환가액의조정(제1회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB) due to a capital increase (rights offering). This type of disclosure is a standard corporate action related to capital structure and financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most appropriate as it covers updates on financing activities and capital structure changes, including adjustments to convertible securities.
2021-08-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.